CCNU and bleomycin in the treatment of cancer: a Southwest Oncology Group Study.
CCNU and Bleomycin, alone or in combination, were used to treat 397 evaluable cases of advanced cancer. Responses defined as 50% or greater reduction in all tumor masses occurred in 13/35 lymphomas, 8/50 brain cancers, and 28/312 other solid tumors. Hematologic toxicity of a life-threatening degree occurred in 33/298 patients evaluable for CCNU toxicity; in an additional 50 it was considered severe. Pulmonary toxicity was severe in 4 patients. Drug-associated deaths (4) included one each due to leukopenia and thrombocytopenia after CCNU; one due to pulmonary toxicity after Bleomycin; and one due to shock after the 20th dose of Bleomycin. There was no suggestion of synergism or additive activity with the two drugs.
D000230:Adenocarcinoma / Q000188:drug therapy; D001761:Bleomycin / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D001854:Bone Marrow Cells; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007958:Leukocyte Count; D008130:Lomustine / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D008223:Lymphoma / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D012075:Remission, Spontaneous; D013997:Time Factors
D009607:Nitrosourea Compounds; D001761:Bleomycin; D008130:Lomustine